公司概述
Clover Health Investments, Corp. operates as a provider of Medicare Advantage plans within the United States, specifically targeting Medicare-eligible individuals through preferred provider organization and health maintenance organization structures. Additionally, the entity manages Clover Assistant, a software platform designed to assist physicians in detecting and managing health-related issues. This organization functions within the Healthcare sector, specifically the Healthcare Plans industry, positioning it as a key player in the managed care landscape. The company currently maintains a market capitalization of $1.00B, with an annual trailing twelve-month revenue of $1.92B and an employee base of 724. These valuation and revenue figures indicate that while the company has achieved significant scale in terms of revenue generation, its relatively small market cap suggests the market may be pricing in specific risks or expecting a distinct trajectory in profitability that differs from its revenue growth rate.
财务健康
The company reported a revenue of $1.92B over the trailing twelve months, yet recorded a net income of $-85,549,000 and an EBITDA of $-85,343,000. The substantial gap between the $1.92B revenue and the significant net losses reveals a cost structure where operating expenses and provisions for losses heavily outweigh the gross earnings generated from premiums. Free cash flow stands at $-35,821,624, which indicates that the company is currently burning cash rather than generating liquidity, thereby limiting its immediate financial flexibility for capital expenditures or debt repayment without external financing. The gross margin is 18.5%, suggesting that after direct costs of services, the company retains a moderate portion of revenue, while the operating margin of -10.1% and profit margin of -4.4% highlight substantial overhead costs and the challenge of converting revenue into actual profit. On the balance sheet, the company holds $120.26M in cash against $0 in debt, resulting in a debt-to-equity ratio that is effectively N/A due to the absence of debt, which portrays a highly conservative capital structure free from leverage obligations. The current ratio is 1.47, indicating that the company possesses sufficient current assets to cover its current liabilities, reflecting a healthy short-term liquidity position despite the operating losses. Furthermore, the return on equity is -26.3% and the return on assets is -9.5%, metrics that reveal that management has not yet been effective in generating positive returns on the capital invested by shareholders or utilized in assets.
估值评估
The trailing twelve-month P/E ratio is N/A due to the negative earnings, while the forward P/E is listed at 21.22, implying that the market is pricing in expectations of future earnings recovery rather than current profitability. The price-to-book ratio stands at 3.21, indicating that the market values the company at more than three times its book value, which suggests a significant premium over the net asset value or high expectations for future growth. Alternative valuation metrics show a price-to-sales ratio of 0.52 and an EV/EBITDA of -10.33, suggesting that traditional earnings-based multiples are not applicable, and valuation relies heavily on revenue multiples and future cash flow potential. The stock has traded between a 52-week high of $3.92 and a 52-week low of $1.58, with the current trading price positioned within this historical range. The beta value is 2.25, which means the stock price is expected to exhibit volatility more than twice that of the broader market, reflecting higher sensitivity to market fluctuations.
Growth & Income
Revenue growth year-over-year is 44.7%, while earnings growth is N/A due to the company's negative net income position. The absence of earnings growth data combined with strong revenue expansion implies that top-line growth is outpacing bottom-line profitability, a common characteristic in growth-stage healthcare companies focusing on market penetration. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are reinvested back into the business to fund operations and growth initiatives rather than being distributed to shareholders. This growth-oriented profile prioritizes capital allocation toward business expansion and technology development over immediate income generation for investors.